Nathan J. Stanley

Nathan J. Stanley

Auto-generated profile, based on publicly available information

Nathan J. Stanley

School of Chemical Engineering and Advanced Materials

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2020 in Nanoscale
Verified
Journal Article
Closed access
PDF file
KHKamrul Hassan
Kamrul Hassan
MNMd. Julker Nine
Md. Julker Nine
TTTran Tung
Tran Tung
NSNathan Stanley
Nathan Stanley
Pei Lay YapPei Lay Yap
Pei Lay Yap
Dusan LosicDusan Losic
Dusan Losic
Graphene and related 2D materials offer an ideal platform for next generation disruptive technologies and in particular the potential to produce printed electronic devices with low cost and high throughput.

1 February 2016 in Cell Metabolism
Verified
Journal Article
Open access
ALAngela Logan
Angela Logan
VPVictoria R. Pell
Victoria R. Pell
KSKarl J. Shaffer
Karl J. Shaffer
CECameron Evans
Cameron Evans
NSNathan J. Stanley
Nathan J. Stanley
MMMichael P. Murphy
Michael P. Murphy
The mitochondrial membrane potential (Δψm) is a major determinant and indicator of cell fate, but it is not possible to assess small changes in Δψm within cells or in vivo. To overcome this, we developed an approach that utilizes two mitochondria-targeted probes each containing a triphenylphosphonium (TPP) lipophilic cation that drives their accumulation in response to Δψm and the plasma membrane potential (Δψp). One probe contains an azido moiety and the other a cyclooctyne, which react together in a concentration-dependent manner by "click" chemistry to form MitoClick. As the mitochondrial accumulation of both probes depends exponentially on Δψm and Δψp, the rate of MitoClick formation is exquisitely sensitive to small changes in these potentials. MitoClick accumulation can then be quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). This approach enables assessment of subtle changes in membrane potentials within cells and in the mouse heart in vivo.

30 May 2017 in Chemical Science
Verified
Journal Article
Open access
PDF file
JKJui Thiang Brian Kueh
Jui Thiang Brian Kueh
NSNathan J. Stanley
Nathan J. Stanley
RHRussell J. Hewitt
Russell J. Hewitt
LWLaura M. Woods
Laura M. Woods
LLLesley Larsen
Lesley Larsen
DLDavid S. Larsen
David S. Larsen
A prodrug strategy for the release of the gasotransmitter CO at physiological pH, based upon 3a-bromo-norborn-2-en-7-one Diels–Alder cycloadducts of 2-bromomaleimides and 2,5-dimethyl-3,4-diphenylcyclopentadienone has been developed. Examples possessing protonated amine and diamine groups showed good water solubility and thermal stability. Half-lives for CO-release in TRIS-sucrose buffer at pH 7.4 ranged from 19 to 75 min at 37 °C and 31 to 32 h at 4 °C. Bioavailability in rats was demonstrated by oral gavage and oCOm-21 showed a dose dependent vasorelaxant effect in pre-contracted rat aortic rings with an EC50 of 1.6 ± 0.9 μM. Increased intracellular CO levels following oCOm-21 exposure were confirmed using a CO specific fluorescent probe.

1 June 2013 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
YLYibai Li
Yibai Li
JCJanet K. Coller
Janet K. Coller
MHMark R Hutchinson
Mark R Hutchinson
KKKathrin Klein
Kathrin Klein
UZUlrich M. Zanger
Ulrich M. Zanger
ASAndrew A Somogyi
Andrew A Somogyi
Ketamine is primarily metabolized to norketamine by hepatic CYP2B6 and CYP3A4-mediated N-demethylation. However, the relative contribution from each enzyme remains controversial. The CYP2B6*6 allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in ketamine metabolism. We examined the N-demethylation of individual ketamine enantiomers using human liver microsomes (HLMs) genotyped for the CYP2B6*6 allele, insect cell–expressed recombinant CYP2B6 and CYP3A4 enzymes, and COS-1 cell–expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant. Effects of CYP-selective inhibitors on norketamine formation were also determined in HLMs. The two-enzyme Michaelis-Menten model best fitted the HLM kinetic data. The Michaelis-Menten constants (Km) for the high-affinity enzyme and the low-affinity enzyme were similar to those for the expressed CYP2B6 and CYP3A4, respectively. The intrinsic clearance for both ketamine enantiomers by the high-affinity enzyme in HLMs with CYP2B6*1/*1 genotype were at least 2-fold and 6-fold higher, respectively, than those for CYP2B6*1/*6 genotype and CYP2B6*6/*6 genotype. The Vmax and Km values for CYP2B6.1 were approximately 160 and 70% of those for CYP2B6.6, respectively. N,N′N′-triethylenethiophosphoramide (thioTEPA) (CYP2B6 inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations. The degree of inhibition was significantly reduced in HLMs with the CYP2B6*6 allele (gene-dose P < 0.05). These results indicate a major role of CYP2B6 in ketamine N-demethylation in vitro and a significant impact of the CYP2B6*6 allele on enzyme-ketamine binding and catalytic activity.

1 December 2010 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
NSN.J. Stanley
N.J. Stanley
DPD. Sejer Pedersen
D. Sejer Pedersen
BNB. Nielsen
B. Nielsen
TKT. Kvist
T. Kvist
JMJ.M. Mathiesen
J.M. Mathiesen
AAA.D. Abell
A.D. Abell